Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 261.4
(2.83%)
SEK 261.4
(2.83%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 11.35 Billion SEK | 258.12% |
| 2022 | 3.17 Billion SEK | -64.86% |
| 2021 | 9.02 Billion SEK | -13.6% |
| 2020 | 10.44 Billion SEK | -36.55% |
| 2019 | 16.46 Billion SEK | 550251.05% |
| 2018 | 2.99 Million SEK | -99.72% |
| 2017 | 1.07 Billion SEK | -53.62% |
| 2016 | 2.31 Billion SEK | 190.65% |
| 2015 | 795.15 Million SEK | 0.43% |
| 2014 | 791.77 Million SEK | 0.13% |
| 2013 | 790.77 Million SEK | 31.8% |
| 2012 | 600 Million SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 1.97 Billion SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 11.47 Billion SEK | 5.61% |
| 2024 Q2 | 10.86 Billion SEK | -4.73% |
| 2024 Q1 | 11.57 Billion SEK | 0.41% |
| 2023 Q4 | 11.35 Billion SEK | -35.76% |
| 2023 Q1 | 3.16 Billion SEK | -0.13% |
| 2023 Q3 | 17.67 Billion SEK | 1.09% |
| 2023 FY | 11.35 Billion SEK | 258.12% |
| 2023 Q2 | 17.48 Billion SEK | 452.16% |
| 2022 Q1 | 8.62 Billion SEK | -4.43% |
| 2022 Q3 | 8.35 Billion SEK | -0.5% |
| 2022 Q2 | 8.4 Billion SEK | -2.6% |
| 2022 FY | 3.17 Billion SEK | -64.86% |
| 2022 Q4 | 3.17 Billion SEK | -62.06% |
| 2021 Q1 | 9.5 Billion SEK | -9.04% |
| 2021 Q4 | 9.02 Billion SEK | -5.64% |
| 2021 Q3 | 9.56 Billion SEK | -1.23% |
| 2021 Q2 | 9.68 Billion SEK | 1.91% |
| 2021 FY | 9.02 Billion SEK | -13.6% |
| 2020 FY | 10.44 Billion SEK | -36.55% |
| 2020 Q1 | 15.34 Billion SEK | -6.79% |
| 2020 Q2 | 12.38 Billion SEK | -19.32% |
| 2020 Q3 | 11.09 Billion SEK | -10.38% |
| 2020 Q4 | 10.44 Billion SEK | -5.86% |
| 2019 Q3 | 8.97 Billion SEK | 52.47% |
| 2019 FY | 16.46 Billion SEK | 550251.05% |
| 2019 Q1 | 6.32 Billion SEK | 211501.47% |
| 2019 Q2 | 5.88 Billion SEK | -6.95% |
| 2019 Q4 | 16.46 Billion SEK | 83.33% |
| 2018 FY | 2.99 Million SEK | -99.72% |
| 2018 Q3 | 4 Million SEK | -20.0% |
| 2018 Q2 | 5 Million SEK | 0.0% |
| 2018 Q1 | 5 Million SEK | -99.53% |
| 2018 Q4 | 2.99 Million SEK | -25.23% |
| 2017 Q4 | 1.07 Billion SEK | 113.1% |
| 2017 Q3 | 503 Million SEK | 0.2% |
| 2017 Q2 | 502 Million SEK | 0.0% |
| 2017 Q1 | 502 Million SEK | -78.28% |
| 2017 FY | 1.07 Billion SEK | -53.62% |
| 2016 Q1 | 802 Million SEK | 0.86% |
| 2016 Q2 | 502 Million SEK | -37.41% |
| 2016 Q3 | 502 Million SEK | 0.0% |
| 2016 Q4 | 2.31 Billion SEK | 360.38% |
| 2016 FY | 2.31 Billion SEK | 190.65% |
| 2015 Q2 | 819 Million SEK | 0.24% |
| 2015 FY | 795.15 Million SEK | 0.43% |
| 2015 Q3 | 820 Million SEK | 0.12% |
| 2015 Q4 | 795.15 Million SEK | -3.03% |
| 2015 Q1 | 817 Million SEK | 3.19% |
| 2014 Q1 | 794 Million SEK | 0.41% |
| 2014 Q3 | 815.4 Million SEK | 0.07% |
| 2014 Q4 | 791.77 Million SEK | -2.9% |
| 2014 FY | 791.77 Million SEK | 0.13% |
| 2014 Q2 | 814.8 Million SEK | 2.62% |
| 2013 Q1 | 800 Million SEK | 33.33% |
| 2013 FY | 790.77 Million SEK | 31.8% |
| 2013 Q4 | 790.77 Million SEK | -0.43% |
| 2013 Q3 | 794.2 Million SEK | -0.73% |
| 2013 Q2 | 800 Million SEK | 0.0% |
| 2012 Q1 | 964.7 Million SEK | 0.0% |
| 2012 Q2 | 461.5 Million SEK | -52.16% |
| 2012 Q3 | 452.4 Million SEK | -1.97% |
| 2012 Q4 | 600 Million SEK | 32.63% |
| 2012 FY | 600 Million SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q1 | 1.95 Billion SEK | -0.69% |
| 2011 Q2 | 1.45 Billion SEK | -25.68% |
| 2011 Q3 | 1.41 Billion SEK | -2.54% |
| 2011 Q4 | - SEK | -100.0% |
| 2010 FY | 1.97 Billion SEK | 0.0% |
| 2010 Q4 | 1.97 Billion SEK | -7.78% |
| 2010 Q3 | 2.13 Billion SEK | 174.67% |
| 2010 Q2 | 777.8 Million SEK | -1.41% |
| 2010 Q1 | 788.9 Million SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | -42986.963% |
| Enzymatica AB (publ) | 24.88 Million SEK | -45535.75% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -3747754.785% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | -327445.428% |
| Nanexa AB (publ) | 2.08 Million SEK | -544030.331% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | -2432.56% |
| Probi AB (publ) | 38.21 Million SEK | -29618.413% |
| Swedencare AB (publ) | 1.44 Billion SEK | -687.954% |
| Toleranzia AB | 850 Thousand SEK | -1335900.0% |
| Vivesto AB | 5.18 Million SEK | -219085.485% |